Nanotechnology-enabled immunogenic cell death for improved cancer immunotherapy

Area of Science:

• Oncology
• Immunology
• Nanotechnology

Background:

• Tumor immunotherapy, particularly cancer immunotherapy, has seen significant advancements.
• Tumor immunogenic cell death (ICD) is a promising strategy for cancer therapy.
• Nanoparticles offer advantages for drug delivery, including stability and tumor targeting.

Approach:

• This review summarizes nanoparticle strategies for delivering ICD inducers in cancer immunotherapy.
• It discusses various nanoparticle types like liposomes, nanostructured lipid carriers, and inorganic nanoparticles.
• The review analyzes the advantages and disadvantages of these nanoparticle systems.

Key Points:

• Functionally specific nanoparticles improve the specificity and efficiency of ICD induction.
• Diverse nanoparticle platforms are employed to deliver ICD inducers in vivo.
• Addressing challenges in nanoparticle design is crucial for effective ICD therapy.

Conclusions:

• Nanoparticle-mediated delivery of ICD inducers holds significant potential for cancer immunotherapy.
• Optimizing nanoparticulate systems can enhance ICD-induced cancer treatment.
• This review provides insights for developing advanced ICD-mediated cancer immunotherapy strategies.